Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

February 28, 2018

Conditions
CMV Infections
Interventions
BIOLOGICAL

Viralym-C

"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."

Trial Locations (2)

77030

Texas Childrens Hospital, Houston

The Methodist Hospital system, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloVir

INDUSTRY

NCT02313857 - Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) | Biotech Hunter | Biotech Hunter